"10.1371_journal.pone.0150102","plos one","2016-02-23T00:00:00Z","Igor Erjavec; Tatjana Bordukalo-Niksic; Jelena Brkljacic; Danka Grcevic; Gordana Mokrovic; Maja Kesic; Dunja Rogic; William Zavadoski; Vishwas M Paralkar; Lovorka Grgurevic; Vladimir Trkulja; Lipa Cicin-Sain; Slobodan Vukicevic","Laboratory of Mineralized Tissues, Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Zagreb, Croatia; Department of Physiology and Immunology, School of Medicine, University of Zagreb, Zagreb, Croatia; Laboratory for Neurochemistry and Molecular Neurobiology, Molecular Biology Department, Rudjer Boskovic Institute, Zagreb, Croatia; Clinical Hospital Center Zagreb, Zagreb, Croatia; Karos Pharmaceuticals, New Haven, CT, United States of America; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia","Conceived and designed the experiments: IE TBN LCS SV. Performed the experiments: IE TBN JB GM MK WZ. Analyzed the data: IE TBN VT LG LCS. Contributed reagents/materials/analysis tools: DG WZ DR VMP. Wrote the paper: IE TBN VMP LG VT SV.","I have read the journals policy and the authors of this manuscript have the following competing interests: WZ and VMP are employees of Karos Pharmaceuticals which supplied the research with compound LX1032, which is a TPH1 specific inhibitor, and performed HPLC analyses. There are no patents, products in development or marketed products to declare. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2016","02","Igor Erjavec","IE",13,TRUE,4,6,5,6,TRUE,TRUE,FALSE,0,NA,FALSE
